Objective: Discussion and analysis of the effect of the early application of Tirofiban on acute ischemic stroke (AIS) after intravenous thrombolysis with urokinase. Method: The subjects of this study are 40 patients with AIS admitted at the Yibin Fourth People’s Hospital, of which were computer-randomized into a control group (20 cases, with regular urokinase intravenous thrombolysis therapy) and a research group (20 cases, combined with early Tirofiban treatment) from January 2018 to December 2022. The intervention outcomes between these two groups were compared and analyzed. Result: The blood platelet-related parameters before treatment had no statistical difference between the two groups (P > 0.05), but the research group was higher than that of the control group after treatment (P < 0.05). The Barthel index before treatment in both groups had no statistical difference (P > 0.05), but the research group was higher than that of the control group after treatment (P < 0.05). Conclusion: Early Tirofiban treatment for patients with AIS after intravenous thrombolysis with urokinase could effectively regulate the blood platelet-related parameters, hence improving treatment benefits and living capacity for patients, with definite clinical benefits.
Lv Y, Liu Y, Li H, et al, 2023, Research on Efficacy of Tirofiban Combined with Alteplase Intravenous Thrombolysis in the Treatment of Mild to Moderate Acute Ischemic Stroke and TOAST Subtypes. Journal of Practical Cardio-Cerebro-Pulmonary Vascular Disease, 31(1): 112–118.
Shi H, Hou M, Sun B, et al, 2021, Application and Research Progress of Tirofiban in the Treatment of Acute Ischemic Stroke. Chinese Journal of Practical Medicine, 38(11): 1309–1313
Mu P, Liu X, Wang M, et al, 2012, Effect of Early Application of Tirofiban on Acute Ischemic Stroke after Intravenous Thrombolysis with Urokinase and on Platelet Indexes. Thrombosis and Haemostasis, 28(1): 54–55 + 58.
Sun Y, Zhang H, Liu B, et al, 2021, Efficacy of Tirofiban on Platelet Related Parameters in Patients with Acute Ischemic Stroke after Intravenous Thrombolysis with Urokinase. Journal of North Sichuan Medical College, 36(2): 197–200.
Zhang L, Hui X, Liu J, et al, 2020, Meta-Analysis: Safety and Efficacy of Tirofiban in the Treatment of Acute Ischemic Stroke. Journal of Stroke and Neurological Disease, 37(7): 594–599.
Huang S, Zhou F, Zhang Y, 2018, Research Progress of Tirofiban in Acute Ischemic Stroke. Chinese Journal of Cerebrovascular Disease, 15(11): 601–606.
Chen J, Wang X, Li G, et al, 2012, Effect of Early Tirofiban Treatment on Clinical Prognosis of Acute Anterior Circulation Moderate Ischemic Stroke with Hyberthrombolytic Time Window. Journal of Clinical Military Medicine, 50(12): 1285–1287 + 1290.
Jiang R, 2012, Efficacy and Safety of Tirofiban in the Treatment of Acute Ischemic Stroke after Intravenous Thrombolysis with Alteplase. Application of Modern Medicine in China, 16(11): 78–81.
Yan Q, Shao Q, Du Q, et al, 2012, Efficacy of Tirofiban in Patients with Acute Ischemic Stroke after Thrombolysis. Chinese Medical Innovation, 19(6): 1–5.
Dai L, Chen S, Su Q, et al, 2021, Clinical Efficacy of Tirofiban Combined with Alteplase Intravenous Thrombolysis in The Treatment of Elderly Patients with Acute Ischemic Stroke. Journal of Rational Drug Use in Clinic, 15(18): 71–74.